<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; significant</title>
	<atom:link href="http://www.tapanray.in/tag/significant/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Could M&amp;As in Pharma create significant stakeholder value?</title>
		<link>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=could-mas-in-pharma-create-significant-stakeholder-value</link>
		<comments>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/#comments</comments>
		<pubDate>Mon, 25 Apr 2011 01:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[consolidation]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=269</guid>
		<description><![CDATA[At the very outset, I pay my homage to the departed soul of our industry colleague respected Amar Lulla, former joint managing director of Cipla, who passed away on Friday, April 22, 2011 after a prolonged battle against cancer. As &#8230; <a href="http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With significant competitive edge should Global Biotech Companies consider entry into high potential ‘Biosimilar drugs’ business?</title>
		<link>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business</link>
		<comments>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/#comments</comments>
		<pubDate>Thu, 07 May 2009 01:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[consider]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=895</guid>
		<description><![CDATA[‘Biosimilar drugs’ – rapid future growth potential: In most of the developed countries of the world, besides regulatory issues, ‘Biosimilar drugs’are considered a threat to the fast growing global biotech industry. However, many believe that innovative biotech companies can have &#8230; <a href="http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare services in India &#8230; growing disparity between urban and rural population – can ‘Telemedicine’ play a significant role?</title>
		<link>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role</link>
		<comments>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/#comments</comments>
		<pubDate>Sun, 05 Apr 2009 06:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[disparity]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[e-healthcare]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[play]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=923</guid>
		<description><![CDATA[Healthcare Industry in India is currently valued at US$ 35 billion. This industry is expected to record a turnover of US$ 75 billion in 2012 and US$ 150 billion in 2017, reports Technopak Advisors in their report titled “India Healthcare &#8230; <a href="http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
